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Abstract
The tumor microenvironment (TME) exerts critical pro-tumorigenic effects through cytokines and 
growth factors that support cancer cell proliferation, survival, motility and invasion. Insulin-like 
growth factor-1 (IGF-1) and Signal transducer and activator of transcription 3 (STAT3) stimulate 
colorectal cancer (CRC) development and progression via cell autonomous and 
microenvironmental effects. Using a unique inhibitor, NT157, which targets both IGF-1 receptor 
(IGF-1R) and STAT3, we show that these pathways regulate many TME functions associated with 
sporadic colonic tumorigenesis in CPC-APC mice, in which cancer development is driven by loss 
of the Apc tumor suppressor gene. NT157 causes a substantial reduction in tumor burden by 
affecting cancer cells, cancer-associated fibroblasts (CAF) and myeloid cells. Decreased cancer 
cell proliferation and increased apoptosis were accompanied by inhibition of CAF activation and 
decreased inflammation. Furthermore, NT157 inhibited expression of pro-tumorigenic cytokines, 
chemokines and growth factors, including IL-6, IL-11 and IL-23 as well as CCL2, CCL5, CXCL7, 
CXCL5, ICAM1 and TGFβ; decreased cancer cell migratory activity and reduced their 
proliferation in the liver. NT157 represents a new class of anti-cancer drugs that affect both the 
malignant cell and its supportive microenvironment.
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INTRODUCTION
Colorectal cancer (CRC) is the third most commonly diagnosed cancer, with approximately 
1.2 million new cases each year. Improved early detection and patient stratification have 
resulted in a significant reduction of mortality, but most of the improvement has been limited 
to early stage CRC (stages I and II), and in patients with advanced stage III and IV disease, 
morbidity and mortality remain high1. CRC originates from epithelial cells at the base of 
intestinal crypts, which accumulate activating oncogenic mutations with concomitant loss of 
tumor suppressor genes, especially APC2. About 2–3% of all CRC cases are associated with 
pre-existing inflammation and are referred to as colitis associated cancer, or CAC3, whose 
development is highly dependent on NF-κB signaling in tumor-associated macrophages 
(TAM), which leads to indirect activation of STAT3 in pre-malignant intestinal epithelial 
cells (IEC)4,5.
STAT3, a crucial and well-known mediator of malignant progression in CRC5,6, is 
predominantly activated by IL-65 and IL-117. Immune cells and cancer-associated 
fibroblasts (CAF) within the TME actively contribute to sustained STAT3 activation in CRC. 
Secretion of IL-11 by TGF-β-stimulated CAF triggers STAT3 signaling in cancer cells8, and 
IL-6 produced by TAM protects normal and premalignant IEC from apoptosis also through 
STAT3 activation5. Moreover, activation of IL-6-STAT3 signaling in normal gastric 
fibroblasts contributes to their conversion into CAF9. Such findings indicate that tumor 
development is highly dependent on intricate interactions between multiple cell types, in 
addition to malignant epithelial cells that harbor oncogenic mutations3,10,11. We found that 
inflammatory processes also play a critical role in development of sporadic CRC, which is 
driven by APC loss12. Absence of APC in IEC results in rapid loss of several components of 
the epithelial barrier that prevent invasion of the colonic mucosa by components of the 
endogenous microbiome, thereby leading to highly elevated expression of the key 
inflammatory cytokine IL-23 in myeloid cells12. By expanding the number of IL-17-
producing cells, IL-23 provides a supportive inflammatory microenvironment that 
accelerates tumor progression12,13.
The TME, which is enriched in immune cells including TAM and various lymphocytes, as 
well as CAF, can also affect the response to therapy in many cancers, including CRC14,15. 
Anticancer drugs are frequently rendered ineffective against cancer cells that are co-cultured 
with stromal cells16. For this reason, identification of therapeutic targets that concomitantly 
affect the malignant behavior of cancer cells and the supportive function of the TME is of 
particular importance. Although targeted biological therapy is rapidly becoming the standard 
of care in advanced CRC17, very few targeted therapeutics were found to affect the TME. Of 
note, antagonists of epidermal growth factor receptor (EGFR) mainly affect malignant 
epithelial cells, but inhibitors of vascular endothelial growth factor (VEGF) target the TME 
and block its ability to stimulate tumor angiogenesis but have no direct activity on cancer 
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cells17. Therefore, EGFR and VEGF inhibitors need to be combined, in order to target both 
the malignant cell and its supportive microenvironment.
In addition to STAT3, another potential therapeutic target in CRC is the ubiquitously 
expressed insulin-like growth factor 1 receptor (IGF-1R), which is involved in diverse 
processes, including mitogenesis, cell survival and differentiation18,19. In vitro experiments 
and epidemiological studies have suggested that IGF-1R participates in the pathogenesis of 
many neoplastic diseases, including CRC19–21. Elevated IGF-1R and IGF-1 expression 
correlates with tumor progression and poor prognosis in several cancer types including 
gastrointestinal malignancies21,22. Genetic polymorphisms in genes encoding IGF-1R 
signaling components and increased circulating IGF-1 or IGF-2 were detected in CRC 
patients23–25. In addition, IGF-1R-driven PI3K/AKT signaling, predicts poor survival in 
CRC independently of the KRAS mutational status25. Furthermore, IGF-1R signaling 
contributes to resistance to cytotoxic26, radiation27 and targeted28–30 therapies. Importantly, 
the pro-oncogenic activities of IGF-1R are highly dependent on its proximal downstream 
effectors: insulin receptor substrate 1 (IRS1), and IRS231,32. IRS1 is upregulated in primary 
and metastatic human CRC compared to the normal colonic epithelium33. ApcMIN mice, 
which carry an inactivating somatic mutation in the murine Apc gene, develop significantly 
fewer intestinal adenomatous polyps when the Irs1 gene is inactivated32.
The involvement of IRS proteins in tumor progression, metastasis and acquired drug 
resistance31,34,35 establishes them as potential and novel targets for anti-cancer drugs. With 
that in mind, NT157 was developed as a prototypic, first-in-class, compound that binds to an 
allosteric site on IGF-1R and induces a conformational change, which results in dissociation 
of receptor-bound IRS1 and IRS2 proteins35. This allows IGF-1R to interact more strongly 
with the adaptor protein Shc, resulting in enhanced activation of ERK, which mediates 
serine phosphorylation and subsequent proteolysis of IRS proteins. Eventually, NT157 leads 
to long-lasting IGF-1R inhibition, cancer cell apoptosis and additional antitumor effects, 
independently of IGF-1 binding35. Another IGF-1R-independent effect of NT157 is the 
dephosphorylation of STAT3 (see accompanying manuscript). The ability of NT157 to 
inhibit two different signaling pathways critical for CRC development drove us to test its 
activity in both sporadic and metastatic CRC mouse models. We now show that NT157 
prevents colorectal tumor development, leads to durable regression of established tumors 
and attenuates growth in the liver metastatic niche. In addition to having direct effects on 
cancer cells, NT157 inhibits critical components of the TME, including CAF and TAM. 
Thus, NT157 is a new type of therapeutic compound that, as a single agent, concomitantly 
targets two essential signaling pathways in malignant cells and components of their 
supportive microenvironment, resulting in strong and pluripotent anti-cancer activity.
RESULTS
NT157 reduces tumor burden in CPC-APC mice
We used a mouse model of sporadic colorectal tumorigenesis, the CPC-APC mouse, in 
which one Apc tumor suppressor allele is specifically deleted in the distal colonic epithelium 
and the second allele undergoes loss-of-heterozygocity (LOH), the same process that drives 
human CRC development36. APC-deficient intestinal organoids exhibited elevated IGF-1R 
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and IRS1 mRNA expression, whereas colonic tumors from CPC-APC mice showed elevated 
expression of IGF-1R, IRS1 and IRS2 mRNAs (Supplementary Figure 1A,B). IGF-1R was 
widely expressed in several TME cell types, including epithelial cancer cells, CAF and 
myeloid cells (Supplementary Figure 1C). Elevated IGF-1 in the circulation and in tumor-
CM was also observed (Supplementary Figure 1D,E). Consistent with previous results35, 
treatment of APC-deficient intestinal organoids and tumor-bearing mice with NT157 
resulted in a rather rapid decrease in IRS1 abundance (Supplementary Figure 1F–H). 
Encouraged by these results, we subjected CPC-APC mice, which develop colonic 
adenomas at 8 to 10 weeks of age, to either early (initiated at 8 weeks) or late (initiated at 16 
weeks) treatment with NT157 (Figure 1a). In both cases, NT157 treatment significantly 
reduced tumor burden (Figure 1b,c), suggesting a role for the IGF-1R-IRS axis in colonic 
tumor development and maintenance in CPC-APC mice. Kaplan-Meier analysis of the late 
treatment group confirmed that NT157 used as a single agent significantly prolonged 
survival (Figure 1d). Even 7 weeks after treatment termination, tumor size remained 
significantly suppressed in NT157 treated mice (Supplementary Figure 1I). NT157 treatment 
reduced the proliferation and induced apoptosis of cancer cells (Figure 1e,f), along with 
IRS1 Ser-phosphorylation (Figure 1g).
NT157 reduces tumor inflammation and reactive stroma
The IGF-1R-IRS and the IL-6-STAT3 signaling pathways are co-activated in different 
pathological contexts37,38,39. NT157 treatment inhibited STAT3 activation in several cancer 
cells lines (see accompanying manuscript), including murine and human CRC cells and the 
TME (Figure 2a, b, d). NT157 slightly increased SHP2 protein expression in some cell lines, 
but that did not correlate with its effects on STAT3 activation by IL-6, which was 
consistently inhibited (Figure 2c, d). STAT3 stimulates Cox2 gene transcription40 and 
correspondingly NT157 blocked COX-2 expression in the TME (Figure 2a,b). NT157 
treatment also reduced the expression of numerous chemokines, chemokine receptors and 
proinflammatory cytokines, including CCL2, CCR2, CCL5, IL-6, IL-11, IL-22 and IL-23 
(Figure 2e), which was accompanied by a decrease in intratumoral CD11b+ and F4/80+ 
cells, and αSMA-expressing CAF (Figure 2f). Reduced CAF activation was associated with 
decreased collagen type I deposition and fibrogenic genes expression (Supplementary Figure 
2A,B).
NT157 inhibits cancer cell proliferation and signaling
To better understand the cellular targets for NT157, we evaluated which effects are rapidly 
induced by NT157 and which are the consequence of prolonged treatment. We treated 16 
week-old CPC-APC mice with NT157 for one week, and sacrificed them 24 hrs after the last 
dose. Even this short treatment period decreased tumor multiplicity (Figure 2g). After only 
two doses, NT157 reduced the number of proliferative Ki67+ cells in tumors, and induced 
cancer cell death, without affecting the normal tissue (Figure 2h,i). We further evaluated the 
effect of NT157 on TME populations. After short NT157 treatment, no changes in immune 
cell populations in spleen, mesenteric lymph nodes (MLN) and normal colon tissue were 
observed (Supplementary Figure 3A,B). No significant changes in tumoral myeloid-derived 
suppressor cells (CD11b+Gr-1+), dendritic cells (CD11b+MHCII+CD11c+), inflammatory 
macrophages (CD11b+MHCII+F4/80+), or lymphocytes (CD4+, CD8+, NK1.1+ and CD19+) 
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were found, either (Supplementary Figure 3C,D). Also, no changes in RORγt+ or IL-17A-
producing cells in MLN and spleen were observed (Supplementary Figure 3F), neither was 
expression of Th17 signature genes, other than IL-21 (Supplementary Figure 3G). By 
contrast, a substantial reduction in gp38+αSMA+ CAF abundance was observed 
(Supplementary Figure 3E), suggesting that inhibition of CAF activation represents a rapid 
response to NT157 treatment.
Consistent with its ability to induce IRS1 degradation, NT157 led to ERK1/2 activation 
independently of IGF-1 (Figure 3a,b,d and Supplementary Figure 4H). This was 
accompanied by inhibition of the PI3K-AKT-mTOR pathway, as indicated by reduced 
phosphorylation of AKT, ribosomal protein S6 and 4E-BP, especially upon IGF-1 
stimulation (Figure 3a–d and Supplementary Figure 4H). The anti-proliferative effect of 
NT157 in mouse and human CRC cell was reflected in reduced cell viability 
(Supplementary Figure 4A–F) and cyclin D1 expression, and caspase-3 activation at 48 hrs 
after treatment initiation. In APC-deficient organoids, NT157 also inhibited cyclin D1 
expression (Figure 3f). These results indicate that disruption of the IGF-1R-IRS axis inhibits 
downstream signaling pathways that control cancer cell proliferation and survival. A further 
decrease in cell survival and proliferation is likely to be caused by inhibition of STAT3 
activation.
NT157 decreases CRC cell growth in the metastatic niche
IGF-1R signaling and IRS proteins control migratory and invasive behavior of cancer 
cells31,34. In the presence of IGF-1, the MC-38, HCT116 and DLD-1 cell lines displayed 
enhanced migratory behavior, as shown by scratch and boyden chamber assays, and this 
behavior was inhibited by NT157 (Figure 4a–d and Supplementary Figure 4I). Several 
chemokines produced by cancer cells may facilitate migratory behavior41,42. Of note, 
NT157 inhibited expression of CXCL5 and CXCL7 in MC-38 cells incubated with LPS, a 
TLR4 agonist (Supplementary Figure 5A). Although NT157 did not affect the expression of 
CCL20 or CXCL12 in MC-38 cells, it did reduce CCL2 expression (Supplementary Figure 
5A). Long-term treatment with NT157 also decreased the expression of CXCL5, MIP-2γ 
and IL-8 in colonic tumors (Supplementary Figure 5B). To test the effect of NT157 on the 
metastatic growth of CRC cells in liver, we injected MC-38 cells intrasplenically and 
initiated treatment with NT157 one week later (Figure 4e). NT157 treatment significantly 
decreased the size of liver metastases (Figure 4f,g), and reduced cell proliferation within 
metastatic nodules (Figure 4h, i). Importantly, the number of αSMA-expressing cells 
surrounding CRC cells in the liver was also diminished after NT157 treatment (Figure 4h, i). 
These data suggest that NT157 targets CRC cells that migrate, reducing their ability to grow 
at the new site and inhibiting the support they receive from activated myofibroblasts or 
hepatic stellate cells.
NT157 inhibits CAF and macrophage activation
IGF-1 is a well-known autocrine and paracrine inducer of CAF activation15. We isolated 
CAF from CPC-APC mice, and stimulated them with IGF-1. This resulted in increased 
αSMA expression, which was abolished when cells were treated with NT157 (Figure 5a,b). 
NT157 treatment also decreased the induction of collagen type I as well as TGFβ, CTGF and 
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FAP mRNAs (Figure 5b). Activated CAF also produced inflammatory cytokines, including 
IL-6 and IL-11, and matrix metalloproteinases15, including MMP3, which expression was 
also abolished by NT157 (Figure 5b). NT157 also inhibited induction of IL-6, IL-11, 
collagen type I, CTGF and TGFβ mRNAs by other CAF activators, including CTGF and 
TGFβ (Supplementary Figure 6a).
TAM are another important source of tumor-promoting cytokines in CRC3. Although we did 
not observe an obvious effect on the number of TAM after short term NT157 treatment, long 
term NT157 treatment reduced the expression of numerous inflammatory cytokines (Figure 
2d). To test the effect of NT157 treatment on macrophages, we used bone marrow-derived 
macrophages (BMDM). Using LPS as a generic BMDM activator, we found that NT157 
inhibited the induction of IL-6, IL-11 and IL-10 mRNAs (Figure 5c) and the, presumably 
autocrine, activation of STAT3 (Figure 5d). Consistent with these results, NT157 also 
inhibited the induction of IL-23, IL-12, IFNγ and IL-1β mRNAs (Figure 5e). Surprisingly, 
NT157 enhanced the secretion TNF secretion, while inhibiting IL-6 secretion (Figure 5f).
DISCUSSION
In addition to the genetic and epigenetic alterations that account for malignant 
transformation, the TME is another key regulator of tumorigenesis and metastatogenesis. In 
particular, inflammatory cell infiltration and activation in early stages of colorectal 
tumorigenesis enhances proliferation of transformed IEC in which β-catenin has been 
activated, and renders them resistant to apoptotic elimination3,10. This microenvironmental 
effect is responsible for accelerating of tumor progression. Deposition of extracellular matrix 
(ECM) by CAF further facilitates tumor growth and spread through effects on endothelial 
cells that turn on the angiogenic switch14,15. The emergence of the TME as an essential 
driver of malignant progression suggests that therapies that target TME components in 
addition to cancer cells, should have strong anti-tumor activity. Although TME-targeting 
therapies should be less susceptible to development of drug resistance because the TME is 
composed of genetically normal and stable cells, the existence of several distinct and 
interactive cell types within the TME, each relying on different signaling pathways, renders 
this task a difficult one. For instance, anti-angiogenic therapies that target VEGFR on 
endothelial cells were found to upregulate components of the EGFR and FGFR signaling 
pathways in the tumor bed43. Another unexpected effect is exhibited by anti-CCL2 therapy, 
which potentiates metastasis within weeks after its termination, by enhancing macrophage 
recruitment into metastatic sites44. Taking all of these points into consideration, we 
examined the ability of NT157, a novel tyrphostin that can inhibit at least two oncogenic 
signaling pathways, IGF-1R-IRS and JAK-STAT3, to target both carcinoma cells and their 
microenvironment in a mouse model of sporadic CRC. Our results demonstrate that NT157 
effectively reduced tumor multiplicity and size through pleiotropic effects on CRC cells and 
the reactive stroma within which they reside. The rapid inactivation of CAF, and inhibition 
of cancer cell proliferation and viability, as well as cytokine production, result in a less 
reactive microenvironment and a further decrease in myeloid cell infiltration. Importantly, 
the inhibition of STAT3 and IGF-1R-IRS signaling by NT157 prolongs the survival of CPC-
APC mice, in which CRC development is driven by the same genetic and immune 
mechanisms responsible for development of aggressive human CRC12. In fact, weeks after 
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treatment cessation, colonic tumors in NT157-treated CPC-APC mice remain smaller than 
those in non-treated mice, supporting the idea that conversion of the TME compartment to a 
less reactive and less inflamed state along with cancer cell targeting results in severe 
impairment of malignancy. Our results strongly support further clinical evaluation of NT157 
and similar compounds in sporadic human CRC.
At this point, it is difficult to discern whether inhibition of STAT3 or blockade of IGF-1R-
IRS signaling makes a more important contribution to the anti-neoplastic activity of NT157. 
A role for the IGF-1R-IRS axis in the pathogenesis of CRC is supported by human 
association studies. Genetic polymorphisms in genes encoding IGF family members and 
related proteins, including IGF-1 and IGFBP3, are associated with CRC development24. 
Elevated plasma IGF-1 and IGF-1R downstream signaling have been linked to enhanced risk 
of colorectal neoplasia and poor survival21,23–25,45. Importantly, a prospective study of a 
cohort of 210 CRC patients showed that tumor size and depth of invasion significantly 
correlate with IGF-1 and IGF-1R expression23. To closely mimic sporadic human CRC, we 
have used the CPC-APC mouse model, as both depend on loss of the APC tumor suppressor. 
In addition, CPC-APC mice exhibit strong activation of the IL-23-IL-17 cytokine cascade12, 
which predicts rapid progression to metastatic disease in human CRC46. We found that loss 
of APC expression in intestinal organoids and colonic tumors results in upregulation of 
IGF-1R and IRS1 expression, findings that are similar to those made in human CRC. We 
also found that several TME constituents, including CAF and TAM, exhibit activation of 
IGF-1R-IRS signaling, which is likely to be sustained by circulating IGF-1, whose 
concentrations in CPC-APC mice are higher than in control littermates. Combined with 
overexpression of IGF-1R and IRS proteins in CRC cells, elevated IGF-1 secretion into the 
tumor bed results in a strong activation of this pathway. Altogether, these findings justify the 
use of the CPC-APC model for evaluating the therapeutic efficacy of IGF-1R-IRS signaling 
inhibitors.
NT157 was identified as an IGF-1R signaling inhibitor that acts through a novel mechanism: 
binding of NT157 to IGF-1R promotes the detachment of IRS proteins, thereby facilitating 
Shc recruitment and activation of ERK1/2, which eventually phosphorylate IRS proteins and 
induce their degradation35. We have confirmed that in both murine and human CRC cells, 
NT157 activated ERK1/2, independently of IGF-1 binding to IGF-1R, resulting in inhibition 
of AKT activation. We also found that NT157 effectively inhibited the phosphorylation of 
mTORC1 downstream targets, including ribosomal protein S6 and 4EBP1. These effects 
may contribute to the ability of NT157 to inhibit cancer cell proliferation and survival. 
Another mechanism through which NT157 can compromise cancer cell proliferation and 
survival is inhibition of STAT3 activation (see accompanying manuscript). We confirmed 
that NT157 inhibited STAT3 tyrosine phosphorylation not only in colorectal tumors, but also 
in IL-6 treated murine and human CRC cells and LPS-stimulated macrophages. Importantly, 
our previous work indicated that STAT3 activation plays a critical role in the pathogenesis of 
both CAC in mice treated with AOM+DSS5 and sporadic colonic tumorigenesis in CPC-
APC mice12. STAT3 is involved in both the survival and the proliferation of CRC cells10 and 
part of the anti-proliferative effect of NT157 could be due to inhibition of cyclin D1 
expression, which is induced by STAT3. NT157 treatment also inhibited the expression of 
COX-2, which is also encoded by a STAT3 target gene. COX-2 is responsible for production 
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of prostaglandin E2 (PGE2), which stimulates malignant progression by promoting the 
survival of CRC cells and increasing their motility47. PGE2 can also enhance production of 
IL-23 by myeloid cells3, which further stimulates CRC progression through the IL-23-IL-17 
cytokine cascade. Notably, selective COX-2 inhibitors reduce CRC incidence48, although 
they also exacerbate intestinal injury3, thereby limiting their utility. In contrats, inhibition of 
COX-2 expression in colonic tumors by NT157 treatment offers a more selective therapeutic 
option for blocking the production of pro-tumorigenic PGE2 in CRC.
Both CAF and myeloid cells contribute to STAT3 activation in cancer cells by producing 
IL-6 and IL-1112,15. Importantly, the anti-inflammatory and anti-tumorigenic effects of 
NT157 are also manifested in these major TME constituents. TAM are important regulators 
of solid tumor development based on their ability to enhance angiogenic, invasive and 
metastatic programming of neoplastic tissue, and their presence in human cancer usually 
correlates with a worse clinical outcome49. In BMDM stimulated with LPS, NT157 blocked 
the induction of IL-6, IL-11 and IL-10, pro-tumorigenic cytokines that mediate STAT3 
activation, as well as IL-23, IL-12, IFNγ and IL-1β. Surprisingly, however, NT157 enhanced 
TNF secretion in the presence of LPS, while inhibiting IL-6 secretion. The mechanistic basis 
for this phenomenon is far from clear, but it should be noted that no increase in intratumoral 
TNF was observed in NT157-treated CPC-APC mice. Importantly, NT157 treatment also 
decreased expression of several chemokines and chemokine receptors, including CCL2, 
CCR2 and CCL5 both in isolated cells and in tumors. This effect may explain the reduced 
amount of inflammatory infiltrate in colonic tumors of NT157-treated mice. However, 
NT157 did not affect intratumoral Th17 cells or their product, IL-17A. Nonetheless, 
inhibition of colonic tumor growth by NT157 was as extensive as the inhibition afforded by 
IL-17A neutralization, but unlike IL-17A neutralization, which only reduced tumor 
development when applied early13, the tumoricidal effect of NT157 was observed even when 
its administration was delayed until after tumor establishment. Furthermore, the therapeutic 
effect of NT157 was durable and was sustained for at least 7 weeks after treatment cessation 
and prolonged survival.
As cancers progress, their stroma becomes more reactive, phenotypically mimicking tissues 
undergoing wound healing or chronic inflammation. Indeed, many solid human 
malignancies are characterized by desmoplasia, containing high numbers of 
myofibroblasts15. CAF inactivation by NT157 was accompanied by decreased collagen type 
I expression and deposition, and reduced expression of fibrogenic and inflammatory 
cytokines, including CTGF, TGFβ, IL-6 and IL-11. In addition to eliminating the tumor 
supportive functions of the TME, NT157 treatment may also result in improved delivery of 
cytotoxic drugs. Importantly, the effects of NT157 are not limited to the TME and are also 
exerted on malignant epithelial cells. In addition to the inhibitory effects on cell proliferation 
and survival, NT157 also attenuates the migratory and invasive behavior of metastatic CRC 
cells and decreases their ability to proliferate forming metastatic lesions in the liver, the most 
common site of CRC metastasis. Although the precise mechanism by which NT157 inhibits 
liver metastasis remains to be determined, previous studies have revealed an important role 
for IL-6 signaling in this process50. Thus, it is conceivable that the effect of NT157 may be 
related to its ability to inhibit IL-6-induced STAT3 activation.
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In summary, NT157 represents a new type of a multi-pronged therapeutic agent that targets 
at least two major oncogenic signaling pathways (IGF-1R-IRS and JAK-STAT3). 
Importantly, NT157 exerts its effects on several cell types involved in cancer development 
and progression, including malignant epithelial cells, CAF and TAM. This broad and 
pluripotent effect may explain the remarkable anti-tumor activity exhibited by NT157 when 
it was used as a single agent.
METHODS
Cell culture and reagents
HCT-116, SW620, HT29, SW480, DLD-1 cells were obtained from American Type Culture 
Collection (ATCC, Manassas VA, USA), and MC-38 cells from Dr. Shoshana Yakar. Cells 
were maintained in DMEM or RPMI with 10%FBS and 1%penicillin/streptomycin at 37°C 
and 5%CO2. CAF were isolated as described13. BMDM were derived from bone marrow 
and induced to differentiate with M-CSF for 7 days. Organoid cultures of small intestinal 
crypts were established as described13.
NT157 was synthesized by Dr. Salim Joubran from the Jerusalem laboratory and used as 
described35. LPS and IGF-1 were purchased from Sigma-Aldrich (St. Louis, MO, USA); 
and IL-6 from Goldbio.(St. Louis, MO, USA)
Mouse models of CRC
C57BL/6 mice were obtained from Charles River Laboratories. ApcF/F, CDX2-Cre (CPC-
APC) mice were described36. Spontaneous colonic tumorigenesis was analyzed at 17 weeks 
of age, in the case of short-term treatment, or at 20 weeks of age, for late treatment. NT157 
was i.p. injected at 70 mg/kg (in 20% 2-hydroxypropyl-β-cyclodextrin) (Sigma-Aldrich), 
three times a week, until sacrifice. For survival analysis, mice were followed until moribund.
CRC metastasis to liver was studied by intrasplenic injection of 5x105 MC-38 cells into 12 
weeks old C57BL/6 females. Animals were sacrificed 20 days after cell injection.
All animal studies were performed in accordance with UCSD and NIH guidelines and 
regulations for the housing and treatment of laboratory animals.
Protein Immunoblotting
Cells were lysed in NP40 buffer and analyzed by standard immunoblotting protocols. 
Antibodies used were directed against: ERK1/2, phospho-ERK1/2, phospho-STAT3, 
phosphor-Akt S473, IRS1, phospho-IRS1 S636/639, IGF-1R, phospho-S6 ribosomal 
protein, phosphor-4E-BP1, cyclin D1, cleaved caspase 3 (Cell Signaling, Danvers, MA, 
USA); β-catenin, SHP2, IRS1, GAPDH (Santa Cruz Biotechnology, Dallas, TX, USA); and 
α-tubulin (Sigma-Aldrich). Secondary antibodies were from Cell Signaling. Detection was 
done using Clarity™ Western ECL Substrate (Biorad, Hercules, CA, USA). Densitometric 
analysis was perfomed using Quantity One Software (Biorad).
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Immunofluorescence
CAF were treated with NT157 with or without IGF-1 for 24 hrs. Then cells were fixed with 
4%PFA, permeabilized with 0.01%Triton X-100 and blocked in 2%BSA/1%serum, followed 
by overnight incubation with GP38 (eBioscience), vimentin (Cell signaling) and αSMA 
(Abcam, Cambridge, UK) antibodies Secondary fluorescent antibodies were added for 1 hr. 
DAPI was used for nuclear counterstaining. Samples were imaged through a SP5 confocal 
microscope (Leica Microsystems, Buffalo Grove, IL, USA) 24 hrs after mounting.
ELISA
Conditioned medium (CM) was collected from BMDM and analyzed using an IL-6 and TNF 
ELISA kit from eBioscience (San Diego, CA, USA) according to manufacturer’s 
instructions. IGF-1 concentration was determined in serum or CM from tissue explants by an 
ELISA kit from Abcam. IGF-1 amounts in tissues were normalized to tissue weight and 
expressed as pg/ml per mg.
Flow cytometry
Flow cytometric analysis of immune cell populations and CAF was performed by labelling 
fluorescent cells with tagged antibodies against: CD45, CD4, CD8, CD19, NK1.1, CD11b, 
F4/80, Gr1, CD11c, MCH-II, EpCam, GP38 (eBioscience),, CD31 (BD, Franklin Lakes, NJ, 
USA), and α-SMA (Abcam), CAF were determined as 
CD45−EpCAM−CD31−GP38+αSMA+ cells. Intracellular staining for RORγt and IL-17A, 
was performed on MLN and spleen single cell suspensions. Samples were analyzed on a 
Beckman Coulter Cyan ADP flow cytometer (Beckman Coulter, Indianapolis IN, USA), and 
data were analyzed with FlowJo.
Histology
Paraffin-embedded or frozen tissues were stained with H&E, Sirius red, or processed for 
IHC. Antigens were retrieved with preheated 1xCitrate buffer and were detected by staining 
with Ki-67 (Genetex, Irvine, CA, USA), cleaved-caspase 3, phosphorylated-STAT3, IGF-1R 
(Cell Signaling), COX-2, IRS1, PCNA (Santa Cruz), CD11b, GP38 (eBioscience), α-SMA 
(Abcam), F4/80 (Caltag, San Mateo, CA, USA) antibodies. The fraction occupied by the 
positively stained areas was calculated from more than 6 high magnification field (HMF) 
images per group using ImageJ software.
RNA Isolation and Real-Time PCR
Total RNA was extracted and mRNA expression was determined as described13. The data 
are presented in arbitrary units and were calculated by 2ˆ(−delta delta CT) method. Primer 
sequences are listed in Table 1 and were obtained from the NIH qPrimerDepot (http://
mouseprimerdepot.nci.nih.gov).
Migration assay
Motility was measured in a modified Boyden chamber using polycarbonate filters (8μm). 
Cell suspensions were left to attach into the upper chamber for 2 hrs. Cells in the presence or 
absence of NT157 were left to migrate for 6 hrs after adding IGF-1 alone or with NT157 
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into the lower compartment. The membranes were stained using Crystal Violet and the 
transmigrated cells on the lower surface were counted.
Wound healing assay
Cells were plated and left to grow until confluent. After wounding with a pipette tip, cells 
were treated with NT157 and/or IGF-1 for 24 hrs. Images were taken at 0 and 24 hrs, and 
wound size was determined as distance between the edges in pixels.
Statistical analysis
Results are expressed as averages±s.e.m or ±s.d. Data were analyzed by Student t-test using 
GraphPad Prism software. p values< 0.05 were considered statistically significant.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. NT157 treatment reduces colorectal tumor burden
a. CPC-APC mice were i.p. administered 70 mg/Kg NT157 or vehicle (2-hydroxypropyl-β-
cyclodextrin) 3 times a week, starting at 8 (early) or 16 (late) weeks of age, for 3 or 4 weeks 
respectively. Animals subjected to early treatment were allowed to develop tumors and 
tumor burden was analyzed at the same time as in mice subjected to late treatment, i.e. at 20 
weeks of age. b. Tumor multiplicity, size and load. Results are averages ± s.e.m. n=6–12 
animals per group. **p<0.01. ***p<0.005. c. Representative images of CPC-APC tumor-
bearing colons from treated and untreated mice. d. Mice subjected to late treatment were 
evaluated for survival. Moribund animals were sacrificed and survival was determined by 
Kaplan-Meier analysis (n=10–12 animals per group) (p=0.0018). e. Tumor specimens from 
above mice were subjected to IHC and IF analysis using antibodies to the indicated markers.
(scale bars: 100 μm). f. Fractions (in %) occupied by antibody stained areas are shown as 
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averages ± s.e.m. (n=6–10 HMF per group). *p<0.05 and ***p<0.005. g. 16 weeks-old 
CPC-APC mice were treated with NT157 for 4 weeks and sacrificed. Tumors were collected 
and subjected to immunoblot (IB) analysis with indicated antibodies. The results were 
quantitated by densitometry, were calculated as p-IRS1/IRS1 and are presented as means ± 
s.e.m. n=8 tumors per group (6–8 animals per group). ***p<0.005.
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Figure 2. NT157 treatment reduces tumor associated inflammation and CAF activation
CPC-APC mice were subjected to late treatment with NT157 or vehicle as above. Tumors 
were collected and analyzed. a. Tumor sections were analyzed by IHC with indicated 
antibodies (magnification: 40×, zoomed field scale bars: 10 μm). b. Fractions (in %) 
occupied by antibody stained areas in tumor sections from a are shown as averages ± s.e.m. 
(n= 6–10 HMF of 4–5 animals per group). c. MC-38 mouse CRC cells and SW620, HT29, 
DLD-1 and HCT116 human CRC cell lines were incubated with NT157 (3 μM) for the 
indicated times. Cell lysates were subjected to IB analysis and quantitated by densitometry. 
Results are means ± s.e.m (n=2–4 independent experiments). * p<0.05. d. MC-38, SW620, 
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HT29, DLD-1 and HCT116 cells were incubated with IL-6 (50 ng/ml) for 20 min with or 
without NT157. Cell lysates were IB analyzed. Results are means ± s.e.m (n=2–4 
independent experiments). * p<0.05. e. Expression of cytokine and chemokine mRNAs was 
determined by Q-PCR in tumors from 20 weeks old mice subjected to late treatment with 
NT157 or vehicle. Results are means ± s.e.m. (n=7–9 mice per group). * p<0.05, ** p<0.01. 
f. Frozen tumor sections were subjected to IF analysis with the indicated antibodies. Nuclei 
were counter stained by DAPI (scale bars: 100 μm). g. CPC-APC mice (19 weeks old) were 
given NT157 every other day for a total of 4 times, sacrificed and analyzed 24 hrs after the 
last injection. Tumor multiplicity, size and load were determined (n=9–10 mice per group). * 
p<0.05. h. Paraffin-embedded or frozen tumor and tissue sections were subjected to IHC and 
IF analyses as above (scale bars 100 μm). i. Fractions (in %) occupied by antibody stained 
areas in tumor sections from h are shown as averages ± s.e.m. (n= 6 to 10 HMF per group). 
*p<0.05; ***p<0.005.
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Figure 3. NT157 inhibits cancer cell proliferation
a–c. MC-38 cells were treated with IGF-1 (100 ng/ml) with or without NT157 (3 μM). After 
24 hrs, phosphorylation of the indicated proteins was examined by IB analysis and 
quantitated by densitometry. Results are shown as means ± s.e.m.; n=3. * p<0.05, *** 
p<0.005 vs. IGF-1 stimulated cells. d. HT29 cells were treated with IGF-1 (100 ng/ml) with 
or without NT157. After 24 hrs, phosphorylation of the indicated proteins was IB analyzed. 
Figure shows representative blots of 2 independent experiments. e. Expression of the 
indicated proteins in MC-38, HT29 and HCT116 cells was IB analyzed at the indicated 
times after NT157 addition (n=2–3 independent experiments). e. APC-deficient intestinal 
organoids were incubated with or without NT157 for 24 hrs and cyclin D1 expression was 
IB analyzed.
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Figure 4. NT157 treatment decreases the metastatic activity of CRC cells
a, b. HCT116 and MC-38 cells were seeded and grown to confluency. The cell monolayers 
were scratched and the cells were left to grow in the presence of IGF-1 (100 ng/ml) with or 
without NT157 (3 μM). Images were taken at 0 and 24 hrs, and wound size was determined 
after 24 hrs using Axo Vision software (distance between the edges in pixels). Three 
different measurements were recorded from 7–10 fields per condition n=2 independent 
experiments. **** p<0.001 vs. IGF-1 stimulated cells c, d. HCT116 and MC-38 cell 
migration was determined using Boyden chambers. Briefly, 2×105 viable cells were seeded 
on the top compartment and left to attach for 2 hrs, afterwards cells were allowed to migrate 
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in DMEM supplemented with 10% FBS in the presence or absence of NT157 and after 
adding IGF-1 to the lower compartment as a chemotactic agent. After 6 hrs, transmigrated 
cells were stained using crystal violet, photographed and the number of cells per 6 HMF was 
calculated for each condition. Results are averages ± s.e.m. *** p<0.005. e. MC-38 cells 
were injected i.s. into C57BL/6 mice. Seven days later the mice were treated with 70 mg/Kg 
NT157 or vehicle as indicated and sacrificed 20 days after cell inoculation. f. Metastatic 
lesions in liver were enumerated and measured. Results are means ± s.e.m. (n=5–7 mice per 
group). * p<0.05. g. Representative images of livers from above mice and H&E staining of 
liver sections (scale bars: 100 μm) * Indicates tumor tissue h. Paraffin embedded liver 
sections were IF analyzed after staining with indicated antibodies (scale bars: 100 μm) * 
Indicates tumor tissue. i. Positively stained areas per each HMF (high magnification field) 
were quantitated using ImageJ Software. Results are averages ± s.e.m. * p<0.05. (n=7 HMF 
per group).
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Figure 5. NT157 prevents CAF and macrophage activation
a, b. CAF were isolated from tumors of 4 months old CPC-APC mice and after expansion in 
culture, were treated with NT157 (3 μM). and/or IGF-1 (100 ng/ml) for 24 hrs. a. The cells 
were stained with indicated antibodies and analyzed by IF microscopy (scale bars: 100 μm). 
b. RNA was extracted and expression of indicated mRNAs were quantitated by Q-PCR. 
Data are means ± s.d. (n=3). c–f. BMDM isolated from tumor-bearing mice were cultured 
and treated with or without LPS (1 μg/ml) with or without NT157 (3 μM). as indicated. c, e. 
Cytokine mRNA expression was examined by Q-PCR. Data are means ± s.e.m. (n=4). * 
p<0.05, ** p<0.01, *** p<0.005, **** p<0.001 vs. LPS stimulated cells. d. STAT3 
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phosphorylation was evaluated by IB analysis (n=4). f. Secretion of IL-6 and TNF from 
BMDM were measured by ELISA. Data are means ± s.e.m. (n=4). **** p<0.001 vs. LPS 
stimulated cells.
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TABLE 1
Murine sequences of primers used in the qPCR gene-expression analyses.
Gene Name Forward primer sequence (5′-3′) Reverse primer sequence (5′-3′)
CTGF cagtggagatgccaggaga taatttccctccccggttac
αSMA gttcagtggtgcctctgtca actgggacgacatggaaaag
CXCR4 tggaaccgatcagtgtgagt gggcaggaagatcctattga
CXCL12 ccaaactgtgcccttcagat atttcgggtcaatgcacact
CXCR1 ttctgagcttgctgggaaac gggtccttcgcctgtataaga
CCL20 aactgggtgaaaagggctgt gtccaattccatcccaaaaa
CCL22 ccagaaggagcacctggac catgggcagtgagcaaagta
ICAM1 tggtagacagcatttaccctca Ggccaccatcctgttctg
IL-8 tgctcaaggctggtccat Gacatcgtagctcttgagtgtca
MMP3 ccaagtctaactctctggaacctg Agagatttgcgccaaaagtg
MIP-2γ gacagacggcaggagcac Tttcaagcacgcctctctc
IGF-1R cacttgcatgacgtctctcc Gagaatttccttcacaattccatc
IRS1 ctatgccagcatcagcttcc Ttgctgaggtcatttaggtcttc
IRS2 tgactataccgagatggccttt Gaggtgccacgataggttgt
TGFβ tggagcaacatgtggaactc gtcagcagccggttacca
FAP cgcgtaacacaggattcact tcggaggagagtttccaatg
Col IA cccctggtcaagatggtc ctccagcctttccaggttct
ICAM1 tggtagacagcatttaccctca Ggccaccatcctgttctg
IL-17A cagggagagcttcatctgtgt Gctgagctttgagggatgat
IL-17F ttgatgcagcctgagtgtct ttgatgcagcctgagtgtct
IL-21 gacattcatcattgacctcgtg Tcacaggaagggcatttagc
IL-23R ccaagtatattgtgcatgtgaaga agcttgaggcaagatattgttgt
RORγt acctcttttcacgggagga tcccacatctcccacattg
CXCL7 gcccacttcataacctccag Gggtccatgccatcagatt
CXCL5 tagagccccaatctccacac Gagctggaggctcattgtg
CCL2 catccacgtgttggctca Gatcatcttgctggtgaatgagt
CCL5 tgcagaggactctgagacagc Gagtggtgtccgagccata
IL-11 gatgtcctacctccggcat Tcaagagctgtaaacggcg
IL-6 ccaggtagctatggtactcca gctaccaaactggctataatc
CCR2 ggagaaaagccaactccttca Cacagatctctgcctttttgc
TNFα ccctcacactcagatcatctt gctacgacgtgggctacag
IL-1β gcaactgttcctgaactcaact Atcttttggggtccgtcaact
IL-23 tccctactaggactcagccaac Tgggcatctgttgggtct
IL-22 tgacgaccagaacatccaga aatcgccttgatctctccac
IFNγ atctggaggaactggcaaaa Ttcaagacttcaaagagtctgaggta
IFNα acccagcagatcctgaacat Aatgagtctaggagggttgtattcc
IL-4 catcggcattttgaacgag Cgagctcactctctgtggtg
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Gene Name Forward primer sequence (5′-3′) Reverse primer sequence (5′-3′)
IL-10 cagagccacatgctcctaga Gtccagctggtcctttgttt
IL-12 tggtttgccatcgttttgctg Acaggtgaggttcactgtttct
RPL32 gctgccatctgttttacgg Tgactggtgcctgatgaact
GAPDH agcttgtcatcaacgggaag Tttgatgttagtggggtctcg
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